Intelligent Bio Solutions Inc. (INBS) Income Statement
INBS FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsINBS revenue and net income
Where INBS's revenue goes
FY2026Each bar shows an amount and its share of revenue. INBS kept −294.9% of revenue as net income.
INBS profit margins
INBS growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +38.1% | +49.7% | +16.3% | — |
| Gross profit | +64.4% | +84.5% | +0.7% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
INBS quarterly EPS vs estimates
Intelligent Bio Solutions beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 11, 2026.
INBS income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $3.1M | $3.1M | $1.3M | $0 | $2.0M | $188,744 | $0 | $0 | $0 |
| Cost of revenue | $2.2M | $1.8M | $1.7M | $930,204 | $0 | $0 | $0 | — | — | — |
| Gross profit | $2.0M | $1.2M | $1.4M | $326,668 | $0 | $2.0M | $188,744 | — | — | — |
| Research & development | $3.4M | $2.4M | $1.7M | $507,424 | $3.9M | $3.8M | $588,206 | $3.2M | $2.5M | — |
| Sales, general & admin | $10.5M | $8.9M | $9.3M | $4.9M | $4.9M | $3.4M | $2.4M | $3.5M | $2.1M | $172,997 |
| Total operating expenses | $14.7M | $11.9M | $11.7M | $12.9M | $8.3M | $7.6M | $2.8M | $6.7M | $4.6M | $172,997 |
| Operating income | −$12.6M | −$10.6M | −$10.3M | −$12.6M | −$8.3M | −$5.6M | −$2.7M | −$6.7M | −$4.6M | −$173,000 |
| Interest income | $110,329 | $101,522 | $84,822 | $9,676 | $14,426 | $13,806 | $97 | $188 | — | — |
| Interest expense | $10,736 | $60,890 | $167,140 | $223,534 | $7,539 | $1.1M | $457,745 | $664,840 | $453,872 | — |
| Income before taxes | −$12.5M | −$10.6M | −$10.2M | −$10.7M | −$8.3M | −$7.1M | −$3.2M | −$7.4M | −$5.1M | −$312,000 |
| Income taxes | — | — | $132,967 | $190,699 | −$27,925 | $2.5M | $550,263 | −$57,691 | −$36,392 | −$167,000 |
| Net income | −$12.4M | −$10.6M | −$10.2M | −$10.6M | −$8.3M | −$7.0M | −$3.7M | −$7.3M | −$5.0M | −$340,000 |
| EBITDA | −$11.3M | −$9.2M | −$8.8M | −$9.5M | −$8.3M | −$1.8M | −$2.6M | −$6.7M | −$417,000 | −$151,000 |
| EPS (diluted) | −$5.87 | −$2.08 | −$37.38 | −$970.88 | −$1104.27 | −$0.66 | −$51.66 | −$0.19 | — | — |
| Gross margin | 48.6% | 40.8% | 45.8% | 26.0% | — | 100.0% | 100.0% | — | — | — |
| Operating margin | −299.1% | −348.7% | −330.5% | −1,002.1% | — | −281.4% | −1,433.7% | — | — | — |
| Net margin | −294.9% | −346.2% | −326.4% | −845.9% | — | −355.3% | −1,967.8% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | $896,774 | $1.1M | $843,884 | $728,867 | $607,494 | $872,287 | $727,824 | $823,800 | $764,063 | $796,094 |
| Cost of revenue | $897,399 | $815,814 | $437,035 | $896,884 | $508,307 | $689,477 | $384,381 | $825,908 | −$87,734 | $645,311 | $564,815 | $563,763 |
| Gross profit | $248,403 | $244,988 | $459,739 | $214,913 | $335,577 | $39,390 | $223,113 | $46,379 | $815,558 | $178,489 | $199,248 | $232,331 |
| Research & development | $1.5M | $893,979 | $522,113 | $486,169 | $1.5M | $358,351 | $506,944 | $948,752 | $750,094 | $471,313 | $348,452 | $103,947 |
| Sales, general & admin | $8.2M | $2.5M | $2.3M | $2.7M | $1.2M | $2.4M | $1.8M | $1.9M | $2.7M | $2.4M | $1.7M | $2.5M |
| Total operating expenses | $4.5M | $3.4M | $3.1M | $3.1M | $3.4M | $2.8M | $2.5M | $2.9M | $3.6M | $3.1M | $2.2M | $2.8M |
| Operating income | −$4.2M | −$3.1M | −$2.6M | −$2.9M | −$3.1M | −$2.7M | −$2.3M | −$2.9M | −$2.8M | −$3.0M | −$2.0M | −$2.5M |
| Interest income | $47,047 | $49,444 | $5,334 | $8,504 | $9,058 | $17,687 | $21,937 | $52,840 | $70,534 | $10,640 | $3,509 | $139 |
| Interest expense | $3,301 | $4,241 | $56,209 | $3,903 | $10,061 | $15,000 | $13,502 | $22,327 | $54,550 | $42,674 | $32,468 | $37,448 |
| Income before taxes | −$3.9M | −$2.9M | −$2.7M | −$3.0M | −$3.1M | −$2.6M | −$2.3M | −$2.7M | −$2.8M | −$3.0M | −$2.0M | −$2.4M |
| Income taxes | — | — | — | — | $12,883 | — | $7,327 | — | $43,437 | −$9,094 | $25,726 | $30,228 |
| Net income | −$3.9M | −$2.9M | −$2.7M | −$3.0M | −$3.1M | −$2.5M | −$2.2M | −$2.7M | −$2.8M | −$3.0M | −$2.0M | −$2.4M |
| EBITDA | −$3.9M | −$2.6M | −$2.3M | −$2.7M | −$2.8M | −$2.2M | −$1.9M | −$2.4M | −$2.5M | −$2.6M | −$1.7M | −$2.1M |
| EPS (diluted) | −$0.90 | −$1.80 | −$2.82 | −$0.35 | −$0.44 | −$0.44 | −$0.50 | −$0.70 | −$1.34 | −$14.30 | −$20.70 | −$1.04 |
| Gross margin | 21.7% | 23.1% | 51.3% | 19.3% | 39.8% | 5.4% | 36.7% | 5.3% | 112.1% | 21.7% | 26.1% | 29.2% |
| Operating margin | −367.5% | −292.9% | −290.9% | −263.6% | −367.7% | −374.1% | −372.8% | −326.9% | −386.3% | −358.6% | −260.6% | −317.3% |
| Net margin | −341.0% | −269.9% | −298.6% | −268.3% | −366.1% | −349.0% | −370.3% | −307.9% | −382.5% | −361.5% | −257.8% | −304.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in INBS's financial statements (latest annual report filed August 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
INBS financial results
In fiscal year 2026 (ended June 30, 2026), Intelligent Bio Solutions reported revenue of $4.2 million, up 38.1% from the year before. It had a net loss of $12.4 million, a net profit margin of −294.9%. Diluted earnings per share came to −$5.87. Over five years revenue grew at an average rate of 16.3% a year.
See the INBS stock overview for the latest quote and news, or the INBS chart for price history and technical indicators.
INBS income statement FAQ
What is Intelligent Bio Solutions's annual revenue?
Intelligent Bio Solutions reported total revenue of $4.2 million for fiscal year 2026, which ended on June 30, 2026. That was up 38.1% from $3.1 million the previous year.
Is Intelligent Bio Solutions profitable?
No. Intelligent Bio Solutions reported a net loss of $12.4 million in fiscal 2026, a net profit margin of −294.9%; its operating margin was −299.1%.
What is Intelligent Bio Solutions's gross margin?
Intelligent Bio Solutions's gross margin was 48.6% in fiscal 2026: for every $100 of revenue, Intelligent Bio Solutions kept $49 after the direct cost of its products and services.
How much does Intelligent Bio Solutions spend on research and development?
Intelligent Bio Solutions spent $3.4 million on research and development in fiscal 2026, 80.0% of revenue.
How fast is Intelligent Bio Solutions growing?
Revenue grew 16.3% a year on average over the last five fiscal years, from $2.0 million to $4.2 million.
What are Intelligent Bio Solutions's earnings per share?
Intelligent Bio Solutions earned $-5.87 per diluted share in fiscal 2026, compared with $-2.08 a year earlier.
When will Intelligent Bio Solutions report its next earnings?
Intelligent Bio Solutions is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Intelligent Bio Solutions's fiscal year end?
Intelligent Bio Solutions's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on August 19, 2026.